Nature Communications (May 2017)
ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia
- Jean-Baptiste Micol,
- Alessandro Pastore,
- Daichi Inoue,
- Nicolas Duployez,
- Eunhee Kim,
- Stanley Chun-Wei Lee,
- Benjamin H. Durham,
- Young Rock Chung,
- Hana Cho,
- Xiao Jing Zhang,
- Akihide Yoshimi,
- Andrei Krivtsov,
- Richard Koche,
- Eric Solary,
- Amit Sinha,
- Claude Preudhomme,
- Omar Abdel-Wahab
Affiliations
- Jean-Baptiste Micol
- Hematology Department, Inserm UMR1170, Gustave Roussy Cancer Campus Grand Paris
- Alessandro Pastore
- Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College
- Daichi Inoue
- Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College
- Nicolas Duployez
- Laboratory of Hematology and Tumor Bank, INSERM UMR-S 1172, Cancer Research Institute of Lille, CHRU of Lille, University Lille Nord de France
- Eunhee Kim
- School of Life Sciences, Ulsan National Institute of Science and Technology
- Stanley Chun-Wei Lee
- Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College
- Benjamin H. Durham
- Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College
- Young Rock Chung
- Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College
- Hana Cho
- Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College
- Xiao Jing Zhang
- Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College
- Akihide Yoshimi
- Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College
- Andrei Krivtsov
- and Division of Hematology/Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School
- Richard Koche
- Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center
- Eric Solary
- Hematology Department, Inserm UMR1170, Gustave Roussy Cancer Campus Grand Paris
- Amit Sinha
- Basepair, Inc.
- Claude Preudhomme
- Laboratory of Hematology and Tumor Bank, INSERM UMR-S 1172, Cancer Research Institute of Lille, CHRU of Lille, University Lille Nord de France
- Omar Abdel-Wahab
- Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College
- DOI
- https://doi.org/10.1038/ncomms15429
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 13
Abstract
While the role of ASLX1 in haematopoiesis and leukaemia has been heavily studied, the role of ASLX2 is unclear. Here the authors show that ASLX2 is required for normal haematopoietic stem cell self-renewal whereas Asxl2 loss promotes leukemogenesis, thus explaining the frequently observed mutations in AML patients
